CJC-1295 No DAC Research Hub · Evidence Overview

CJC-1295 No DAC research evidence: what has actually been studied?

A careful review of growth-hormone-releasing-hormone analogue research—and why “No DAC” must not be conflated with long-acting CJC-1295.

JD BioWorks Research LibraryPublished: July 15, 2026Last reviewed: July 15, 2026Editorial review: JD BioWorks Research Library

Evidence at a glance

Human evidenceDirect evidence for material specifically described as “CJC-1295 No DAC” is sparse. Frequently cited human studies evaluated long-acting CJC-1295 designed to bind albumin.

Preclinical evidenceGHRH-analogue research supports biological plausibility, but sequence, substitutions, half-life extension, and formulation determine which evidence is relevant.

Evidence gapThe naming used by suppliers is inconsistent, and direct, well-controlled human research on the exact “No DAC” material is not established.

ScopeEvidence for DAC-conjugated CJC-1295 cannot be transferred automatically to a non-DAC analogue. Analytical identity must come before evidence comparison.

Interpretation note: Findings must stay tied to the exact molecule, formulation, model, population, and endpoint studied. A biological signal is not, by itself, proof of safety or effectiveness.

Overview

“CJC-1295” is often used loosely for more than one growth-hormone-releasing-hormone analogue. The best-known clinical studies evaluated a long-acting molecule with a drug-affinity-complex component that forms a covalent bond with albumin. Products marketed as “CJC-1295 No DAC” are generally intended to denote a shorter-acting analogue without that component. These are not interchangeable research identities.

Research background

Two randomized studies published in 2006 evaluated long-acting CJC-1295 in healthy adults and reported sustained changes in growth hormone and IGF-I. A follow-up analysis examined pulsatile secretion under continuous stimulation. Those publications are valuable for the specific molecule studied, but they should not be cited as direct human evidence for a different non-DAC material.

Findings by research area

Research area	What has been reported	What it does not establish
Long-acting CJC-1295	Randomized healthy-volunteer studies reported prolonged pharmacokinetic and pharmacodynamic effects.	Effects of a non-DAC analogue.
No-DAC identity	Supplier terminology commonly distinguishes shorter-acting material from DAC-conjugated CJC-1295.	A universally standardized chemical identity.
GHRH biology	Analogue research can examine pituitary GH release and downstream IGF-I.	Clinical benefit, safety, or dosing for an unstudied material.

Human evidence

Human data

The Teichman studies enrolled healthy adults in randomized, placebo-controlled, ascending-dose protocols using long-acting CJC-1295. They reported sustained increases in measured GH and IGF-I and an estimated multiday half-life. Because albumin binding is central to that pharmacokinetic profile, the results cannot be used to describe the half-life or exposure of a “No DAC” material. Direct controlled human data for the exact material represented on this site were not identified in the primary literature reviewed for this summary.

Preclinical evidence

Animal data

Animal GHRH-analogue studies can explore endocrine signaling, growth, and exposure, but small changes in sequence or conjugation can substantially alter stability and duration. Each test article therefore requires exact sequence and form documentation.

Laboratory evidence

In-vitro and analytical context

Receptor and pituitary-cell assays can compare agonist activity. They cannot establish in-vivo exposure, endocrine pulsatility, or safety, and they do not substitute for mass-spectrometric identity and quantitative purity testing.

Research limitations

The label “CJC-1295 No DAC” is not used consistently across the literature and market.
Frequently cited clinical studies examined a different, long-acting albumin-binding molecule.
Human pharmacokinetics, safety, and outcomes for the exact non-DAC material remain inadequately characterized.
Combination with ipamorelin creates a separate test article and evidence question.

Future research

Research should begin with unambiguous sequence and molecular-form definitions, followed by validated analytical characterization, receptor pharmacology, pharmacokinetics, and staged controlled studies of the exact test article.

Primary references

Article record

Research question: What does the published evidence on CJC-1295 No DAC show across human, animal, and laboratory research?
Evidence cutoff: July 15, 2026
Article status: Published educational research summary; not independently peer reviewed
Author: JD BioWorks Research Library
Editorial review: JD BioWorks Research Library
Planned review cycle: At least annually, or sooner if material evidence or regulatory information changes

This article summarizes published research for educational and laboratory-information purposes. It is not medical advice, does not provide instructions for personal use, and does not establish that any material is safe or effective for human or veterinary use.

CONTINUE YOUR REVIEW

Next steps for qualified researchers

Use the public documentation resources below, then continue to Research Product Access when you are ready to review the gated catalog.

Search Certificates of Analysis Match available analytical records to the named product, quantity, and lot. Explore Research Guides Review HPLC, LC-MS, purity, identity, storage, and traceability guidance. Get Research Product Access Complete the Research Use Acknowledgment to create an account and receive automatic product access.

For qualified laboratory, analytical, educational, or institutional research only. Not for human or veterinary use.